<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170609</url>
  </required_header>
  <id_info>
    <org_study_id>C1091001</org_study_id>
    <nct_id>NCT03170609</nct_id>
  </id_info>
  <brief_title>A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age</brief_title>
  <official_title>A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study
      evaluating the investigational multivalent group B streptococcus vaccine. Healthy adults aged
      18 to 49 years of age with no history of group B streptococcal vaccination will be randomized
      to receive either a single intramuscular dose of multivalent group B streptococcus vaccine
      (various formulations at 3 dose levels) or a placebo (saline control).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Anticipated">June 5, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reporting prompted local reactions within 14 days following investigational product administration (redness, swelling, and pain at the injection site).</measure>
    <time_frame>Day 15</time_frame>
    <description>Describe local reactions after one dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting prompted systemic events within 14 days following investigational product administration (fever, nausea/vomiting, diarrhea, headache, fatigue, muscle pain, and joint pain).</measure>
    <time_frame>Day 15</time_frame>
    <description>Describe systemic events after one dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting adverse events within 1 month following investigational product administration.</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Describe adverse events after one dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of sentinel-cohort subjects with clinical laboratory abnormalities following investigational product administration at the 1-week follow-up visit.</measure>
    <time_frame>Day 7</time_frame>
    <description>Describe clinical laboratory abnormalities in sentinel-cohort subjects after one dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting medically attended adverse events and serious adverse events within 6 months following investigational product administration.</measure>
    <time_frame>6 months after vaccination</time_frame>
    <description>Describe medically attended adverse events and serious adverse events after one dose of investigational product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group B streptococcus serotype-specific immunoglobulin G geometric mean concentrations measured 1 month after vaccination.</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Assess group B streptococcus serotype-specific immunoglobulin G geometric mean concentrations after one dose of investigational product.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Group B Streptococcal Infections</condition>
  <arm_group>
    <arm_group_label>Lowest dose formulation a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent group B streptococcus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose formulation a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent group B streptococcus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Highest dose formulation a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent group B streptococcus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lowest dose formulation b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent group B streptococcus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose formulation b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent group B streptococcus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Highest dose formulation b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent group B streptococcus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multivalent group B streptococcus vaccine</intervention_name>
    <description>Various formulations at three dose levels</description>
    <arm_group_label>Lowest dose formulation a</arm_group_label>
    <arm_group_label>Middle dose formulation a</arm_group_label>
    <arm_group_label>Highest dose formulation a</arm_group_label>
    <arm_group_label>Lowest dose formulation b</arm_group_label>
    <arm_group_label>Middle dose formulation b</arm_group_label>
    <arm_group_label>Highest dose formulation b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline Control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults (male and female) 18 to 49 years of age at enrollment who are
             determined by medical history, physical examination, and clinical judgment of the
             investigator to be eligible for inclusion in the study.

          2. Negative urine pregnancy test at Visit 1 for all female subjects who are of
             childbearing potential.

        Exclusion Criteria:

          1. Male subjects and female subjects of childbearing potential who are unwilling or
             unable to use a highly effective method of contraception as outlined in this protocol
             for at least 3 months after the last dose of investigational product.

          2. Acute or chronic medical or psychiatric condition or laboratory abnormality that may
             increase the risk associated with study participation or investigational product
             administration or may interfere with the interpretation of study results and, in the
             judgment of the investigator, would make the subject inappropriate for entry into this
             study. Chronic medical conditions include human immunodeficiency virus, chronic
             hepatitis B virus (HBV) infection (HBV surface antigen positive), and/or hepatitis C
             virus infection.

          3. History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis)
             to any vaccine.

          4. History of microbiologically proven invasive disease caused by group B streptococcus
             (Streptococcus agalactiae).

          5. Previous vaccination with any licensed or investigational group B streptococcus
             vaccine, or planned receipt during the subject's participation in the study (through
             the last blood draw).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric / Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1091001&amp;StudyName=A+Phase+1%2C+Randomized%2C+Observer+Blinded+Trial+To+Evaluate+The+Safety%2C+Tolerability%2C+And+Immunogenicity+Of+A+Multivalent+Group+B+Streptococcus+Vaccine+In+Healthy+Adults+Aged+18+To+49+Years</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1091001&amp;StudyName=A+Phase+1%2F2%2C+Randomized%2C+Placebo-controlled%2C+Observer-blinded+Trial+To+Evaluate+The+Safety%2C+Tolerability%2C+And+Immunogenicity+Of+A+Multivalent+Group+B+Streptococcus+Vaccine+In+Healthy+Adults+18+To+49+Years+Of+Age</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

